ADC	antibody–drug conjugate
AR	androgen receptor
CBR	clinical benefit rate
CR	complete response
ctDNA	circulating tumor DNA
CPS	combines positive score
CTC	circulating tumor cells
CTLA4	cytotoxic T-lymphocyte-associated protein 4
DCR	disease control rate
DFS	disease-free survival
ER	estrogen receptor
HR	homologous recombination
HR	hazard ratio
HER2	epidermal growth factor receptor 2
ITT	intention to treat
IL	interleukin
NGS	next-generation sequencing
ORR	objective response rate
OS	overall survival
PARP	poly (ADP ribose) polymerase
PR	progesterone receptor
PR	partial response
PD-1	programmed cell death protein 1
PD-L1/2	programmed death-ligand 1/2
PFS	progression-free survival
TNBC	triple-negative breast cancer
VEGF	vascular endothelial growth factor